Suppression of human cancer cell proliferation by lipoxygenase inhibitors and gamma-radiation in vitro.
The effects of inhibitors of arachidonic acid oxidative metabolism, gamma-radiation and/or their combinations on proliferation and cell cycle were studied in human breast carcinoma HS578T and monoblastoid U937 cell lines. While piroxicam an inhibitor of cyclooxygenase pathway, had no significant effects on cell proliferation, inhibitors of lipoxygenase pathway, nordihydroguaiaretic acid and esculetin, suppressed [3H]-thymidine incorporation and cell growth. The latter agents also differed in their modulation of cell cycle parameters depending on the cell line and the time of treatment. When the cells were preirradiated with gamma radiation (5 Gy) and treated with the drugs (at concentrations 50 mumol/l and higher) the effects on cell proliferation were mostly additive. On the other hand, the results suggest that antiproliferative effects could be significantly strengthened when lower doses (25 mumol/l) of lipoxygenase inhibitors were combined with a low dose (1 Gy) of gamma-radiation. Experiments monitoring the reversibility of the effects after single or combined treatment with the agents showed that irradiation suppressed the ability of U937 cells to restore cell proliferation, and that these effects may be strenghtened by esculetin. In conclusion, our results (1) suggest that the lipoxygenase pathway plays a significant role in proliferation of cancer HS578T and U937 cells in vitro, and (2) implicate the possibility of more effective antiproliferative effects after combined treatment of cells with gamma-radiation and lipoxygenase inhibitors.
Hofmanová
J
J
Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic.
Musilová
E
E
Kozubík
A
A
D001943:Breast Neoplasms; D002453:Cell Cycle / Q000187:drug effects* / Q000528:radiation effects*; D002455:Cell Division / Q000187:drug effects* / Q000528:radiation effects*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005720:Gamma Rays; D006801:Humans; D007700:Kinetics; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology*; D009637:Masoprocol / Q000494:pharmacology*; D010894:Piroxicam / Q000494:pharmacology; D013936:Thymidine / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014468:Umbelliferones / Q000494:pharmacology*
D016861:Cyclooxygenase Inhibitors; D004273:DNA, Neoplasm; D016859:Lipoxygenase Inhibitors; D014468:Umbelliferones; D010894:Piroxicam; D009637:Masoprocol; C007628:esculetin; D013936:Thymidine